MedTrace Logo

Do EEG and Neurocognitive Assessments Correlate With COVID Brainfog Symptoms?

NCT05303116 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-05-18

No results posted yet for this study

Summary

Since the neurologic symptoms of some COVID patients ('brain fog') resemble those of patients with concussion, the aim of this study is to identify EEG and cognitive function changes in COVID patients. We will use the FDA cleared BrainScope medical device in conjunction with standard neurocognitive tests to identify correlations with electrical biomarkers and to potentially identify new, unique patterns of altered brain electrical activity associated with COVID-19 infection. A baseline assessment will be performed shortly after hospital presentation and then a second evaluation will be performed 45-60 days post hospital discharge to reassess clinical status, brain electrical biomarkers and neurocognitive performance. The goal will be to develop an objective measurement of brain function/dysfunction associated with COVID-19 infection which might be employed in future studies of treatments for COVID-19 brain fog and to aid in tracking recovery.

Conditions

Interventions

DIAGNOSTIC_TEST

Brainscope modified EEG and cognitive testing

Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.

Sponsors & Collaborators

  • BrainScope Company, Inc.

    collaborator INDUSTRY

  • Texas Tech University Health Sciences Center, El Paso

    lead OTHER

Principal Investigators

  • Edward Michelson, MD · Chair, Dept of Emergency Medicine; TTUHSC El Paso

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2024-02-19
Completion
2024-02-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303116 on ClinicalTrials.gov